Is there a role for interferon in acute viral hepatitis?

R Esteban

Abstract

Acute hepatitis B is a self-limiting disease that resolves spontaneously in 95% of patients who acquire the infection in adulthood. Patients with acute hepatitis B, however, usually take between four and 12 weeks to recover; the personal, social, and sanitary costs associated with this are high. Also, 5–10% of patients with acute hepatitis B go on to develop chronic liver disease. Hepatitis C, by comparison, is an asymptomatic disease associated with a high progression to the chronic stage. At least 50% of patients with post-transfusion hepatitis C develop chronic liver disease or cirrhosis. While the efficacy of alpha interferon in chronic hepatitis B and C is now well established, only preliminary evidence for use in the acute phase exists. This paper reviews the preliminary evidence and concludes that, given the high risk of progression to the chronic stage, the use of interferon in acute hepatitis C should be recommended.

(Gut 1993; supplement: S77–S80)

Infection with hepatitis B virus (HBV) can result in two different clinical pictures, depending upon the age of infection. In the newborn infected by mother to child transmission, hepatitis B infection is usually asymptomatic, associated with high values of viral replication, and mild histological lesions, and becomes chronic in more than 95% of cases. The strategy for preventing this type of infection is obviously the sero-vaccination of those born to hepatitis B surface antigen (HBsAg) positive mothers. This is the pattern of HBV infection seen in countries from South East Asia and Africa in which the prevalence of HBsAg carriers is very high.

In Western countries, HBV infection is mainly acquired during adulthood through sexual or parenteral routes. Infection is often symptomatic, with a clinical picture of acute hepatitis that lasts for five to 12 weeks and eventually resolves spontaneously in 95% of cases.

Acute hepatitis B is a severe disease and its symptoms are poorly tolerated by patients. This has economic and social implications in terms of the cost of health care and the loss of labour. At present, there is no specific treatment for acute hepatitis B. There is justification for the use of a treatment which would shorten the duration of the illness and prevent the development to the chronic stage. Because of the low occurrence of chronic disease, however, it is difficult to obtain the numbers of patients required to study this aspect adequately.

By comparison, hepatitis C virus (HCV) infection usually causes an asymptomatic disease which is associated with a high rate of progression to the chronic state. It is widely accepted that at least 50% of patients with post-transfusion hepatitis C develop chronic liver disease or cirrhosis. Alpha interferon (IFN) has been used in the treatment of chronic hepatitis C as it returns alanine aminotransferase (ALT) activities to normal, improves the inflammatory lesions of the liver, and inhibits HCV replication. Only preliminary evidence exists for the clinical use of interferon alfa in the acute phase of HCV infection.

Hepatitis B

Interferon has been shown to be useful in patients with chronic hepatitis B and acts by inhibiting HBV replication. About 40% of those patients treated lose HBV-DNA and HBsAg. It is reasonable, therefore, to test for the possible efficacy in patients with acute hepatitis B.

Tassopoulos and colleagues designed a clinical trial aimed at establishing whether treatment with interferon in acute hepatitis B could modify the severity and duration of symptoms, the clearance of viral markers, or the titre of neutralising antibodies. The study included 100 patients with acute hepatitis B who were randomised to three groups. Group I comprised 34 patients who received 3 million units (MU) of interferon alfa-2b three times weekly for three weeks. Group II included 33 patients treated with 10 MU of interferon alfa-2b three times weekly for three weeks, and group III, with 33 patients, received placebo for the same period of time.

Interferon was well tolerated in all patients, even those with a prolonged prothrombin time or marked jaundice. None of the patients treated with IFN alfa-2b experienced a flare up of the disease or developed encephalopathy. Although the overall clinical, biochemical, and serological outcome was similar in the three groups, patients in group I, who received 3 MU of interferon, showed a clinical improvement in the signs and symptoms of acute hepatitis appreciably earlier than those in the control group. At the end of treatment, ALT activities and bilirubin values were similar between groups, although in group II, that is in patients treated with 10 MU of IFN, ALT activities returned to normal earlier. There was no
difference in the clearance rate of HBsAg between groups, but women in group I eliminated this marker more rapidly than men. HBV-DNA seemed to become negative in Group I earlier than in the other two groups, although there was not a statistically significant difference. In group I, 91.2% of patients were HBV-DNA positive at onset compared with only 17.6% after two weeks of treatment.

The group that received 10 MU of interferon (Group II) showed higher geometric mean titre (85.1 IU/l) than patients treated with 3 MU (40-7 IU/l) or placebo (35-5 IU/l).1

In summary, the study by Tassopoulos et al2 shows that alpha interferon is well tolerated in acute hepatitis B, even in patients with severe disease. Treatment seems to shorten the period of clinical disease and, as a result of the higher titre of anti-HBs achieved in patients treated with 10 MU TW, might reduce the clinical complications in subjects at risk. The data are promising and deserve further clinical investigation to confirm and expand the results.

Hepatitis C
HCV is transmitted mainly by parenteral routes. Infection is often asymptomatic and is associated with a high rate of progression to the chronic stage. Before the discovery of HCV, it was apparent from studies of post-transfusion hepatitis that a high percentage of patients developed chronicity. Prospective studies show that half the patients had raised ALT activities one year after the acute hepatitis, 41% already had chronic active hepatitis, and 20% had cirrhosis.

HCV infection can eventually lead to the development of hepatocarcinoma. For example, there is the reported case history of a patient who had acute post-transfusion hepatitis, chronic persistent hepatitis, chronic active hepatitis, cirrhosis and, finally, hepatocarcinoma 18 years after transfusion. In our experience, one year after acute post-transfusion hepatitis, 86% of patients had histological lesions indicative of chronic hepatitis, even in some cases when ALT activities are normal.

In summary, although HCV infection leads to very little symptomatic disease, irreversible chronic lesions are common. It seems reasonable, therefore, to start treatment as early as possible to avoid such an outcome.

Clinical evidence
Some preliminary studies have reported the use of IFN during the acute phase of HCV infection to prevent the progression to the chronic stage. There are a few studies with a limited number of patients and different types and doses of interferon, but with follow up periods too short to draw conclusions. For example, Almasio et al2 gave alpha interferon for four weeks to six patients with leukaemia and with acute hepatitis C. Normal ALT activities were achieved in five, although three of them later relapsed. Chemello et al2 treated nine patients with alpha interferon for 12 weeks. After six months, six patients still had normal ALT activities.

Ohnishi et al4 obtained similar results in six patients with acute post-transfusion hepatitis treated with 3 MU three times weekly of human fibroblast β interferon for four weeks. ALT activities fell shortly after the start of treatment and remained normal in all patients six and 12 months after treatment finished. The study by Omata and colleagues5 also deserves emphasis. In a controlled trial of 25 patients, 11 were treated with β interferon for four weeks while 14 patients served as controls. One year after treatment, seven of 11 patients (64%) had normal ALT activities, compared with only one of the controls (7%). After this initial trial, three of four patients who did not respond to interferon achieved normal ALT activities after a second course of treatment. After three years of follow up, HCV-RNA by polymerase chain reaction had become negative in 10 of 11 patients treated with β interferon, suggesting that interferon normalises ALT activities by inhibiting HCV replication.

In our hospital, we designed a randomised, controlled trial of interferon alfa in 28 patients with acute post-transfusion hepatitis C,6 19 were heart surgery patients, four were from general surgery, two from urology, two from gynaecology, and one from internal medicine. Diagnosis was serological. Results from four prospective studies show that half the patients had raised ALT activities one year after the acute hepatitis, 41% already had chronic active hepatitis, and 20% had cirrhosis.

HCV infection can eventually lead to the development of hepatocarcinoma. For example, there is the reported case history of a patient who had acute post-transfusion hepatitis, chronic persistent hepatitis, chronic active hepatitis, cirrhosis and, finally, hepatocarcinoma 18 years after transfusion. In our experience, one year after acute post-transfusion hepatitis, 86% of patients had histological lesions indicative of chronic hepatitis, even in some cases when ALT activities are normal.

In summary, although HCV infection leads to very little symptomatic disease, irreversible chronic lesions are common. It seems reasonable, therefore, to start treatment as early as possible to avoid such an outcome.

Clinical evidence
Some preliminary studies have reported the use of IFN during the acute phase of HCV infection to prevent the progression to the chronic stage. There are a few studies with a limited number of patients and different types and doses of interferon, but with follow up periods too short to draw conclusions. For example, Almasio et al2 gave alpha interferon for four weeks to six patients with leukaemia and with acute hepatitis C. Normal ALT activities were achieved in five, although three of them later relapsed. Chemello et al2 treated nine patients with alpha interferon for 12 weeks. After six months, six patients still had normal ALT activities.

Ohnishi et al4 obtained similar results in six patients with acute post-transfusion hepatitis treated with 3 MU three times weekly of human fibroblast β interferon for four weeks. ALT activities fell shortly after the start of treatment and remained normal in all patients six and 12 months after treatment finished. The study by Omata and colleagues5 also deserves emphasis. In a controlled trial of 25 patients, 11 were treated with β interferon for four weeks while 14 patients served as controls. One year after treatment, seven of 11 patients (64%) had normal ALT activities, compared with only one of the controls (7%). After this initial trial, three of four patients who did not respond to interferon achieved normal ALT activities after a second course of treatment. After three years of follow up, HCV-RNA by polymerase chain reaction had become negative in 10 of 11 patients treated with β interferon, suggesting that interferon normalises ALT activities by inhibiting HCV replication.

In our hospital, we designed a randomised, controlled trial of interferon alfa in 28 patients with acute post-transfusion hepatitis C,6 19 were heart surgery patients, four were from general surgery, two from urology, two from gynaecology, and one from internal medicine. Diagnosis was serological. Results from four prospective studies show that half the patients had raised ALT activities one year after the acute hepatitis, 41% already had chronic active hepatitis, and 20% had cirrhosis.

HCV infection can eventually lead to the development of hepatocarcinoma. For example, there is the reported case history of a patient who had acute post-transfusion hepatitis, chronic persistent hepatitis, chronic active hepatitis, cirrhosis and, finally, hepatocarcinoma 18 years after transfusion. In our experience, one year after acute post-transfusion hepatitis, 86% of patients had histological lesions indicative of chronic hepatitis, even in some cases when ALT activities are normal.

In summary, although HCV infection leads to very little symptomatic disease, irreversible chronic lesions are common. It seems reasonable, therefore, to start treatment as early as possible to avoid such an outcome.
controls (38.5%). The differences between the groups were not statistically significant. At six months, the percentage of patients with normal ALT activities decreased to 46% in the treated group and 31% in the control group.

Results of the liver biopsy performed at 12 months are shown in Fig. 2. Biopsies were performed in 11 patients treated with IFN and in 10 controls. In the treated group, chronic active hepatitis was found in five patients (45.5%), two (18.2%) had chronic persistent hepatitis, and four (36.4%) normal liver on histological examination. Eight of 10 controls (80%) had chronic active hepatitis, and the other two patients had almost normal histology. The Knodell index was lower in the group treated with IFN.

We concluded that IFN is well tolerated in patients with acute hepatitis C, and is effective in returning ALT activities to normal during the first three months of treatment. This effect disappears during follow up as some patients relapse. Histological lesions at 12 months in the treated group, however, are less severe than the lesions in the control group.

Conclusions
Although there are only a limited amount of data available for the treatment of acute hepatitis with IFN, results suggest that IFN should be recommended in acute hepatitis C, given the high risk of progression to the chronic stage. Multicentre trials with a longer duration are needed, however, to evaluate definitively the role of IFN in acute HCV infection.


Is there a role for interferon in acute viral hepatitis?

R Esteban

Gut 1993 34: S77-S80
doi: 10.1136/gut.34.2_Suppl.S77

Updated information and services can be found at:
http://gut.bmj.com/content/34/2_Suppl/S77

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Hepatitis B (88)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/